4D MOLECULAR THERAPEUTICS INC. - COMMON STOCK

4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

06 авг 2025 08:00:00 Источник Nasdaq GlobeNewswire

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update

31 июл 2025 16:05:01 Источник Nasdaq GlobeNewswire

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists

24 июл 2025 08:00:00 Источник Nasdaq GlobeNewswire

4DMT Announces New Employment Inducement Grants

11 июл 2025 16:05:00 Источник Nasdaq GlobeNewswire

4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution

02 июл 2025 16:05:00 Источник Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

28 май 2025 08:00:31 Источник Nasdaq GlobeNewswire

4DMT Announces New Employment Inducement Grants

16 май 2025 16:05:00 Источник Nasdaq GlobeNewswire

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

08 май 2025 16:05:03 Источник Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

05 май 2025 08:00:21 Источник Nasdaq GlobeNewswire

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

01 май 2025 08:00:46 Источник Nasdaq GlobeNewswire

4DMT Announces New Employment Inducement Grants

11 апр 2025 16:05:00 Источник Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

27 мар 2025 08:00:10 Источник Nasdaq GlobeNewswire

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

10 мар 2025 08:00:00 Источник Nasdaq GlobeNewswire

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

28 фев 2025 16:05:00 Источник Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

19 фев 2025 08:00:36 Источник Nasdaq GlobeNewswire

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

08 фев 2025 14:30:24 Источник Nasdaq GlobeNewswire

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

29 янв 2025 08:00:00 Источник Nasdaq GlobeNewswire

4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path

10 янв 2025 08:00:00 Источник Nasdaq GlobeNewswire

4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway

10 янв 2025 08:00:00 Источник Nasdaq GlobeNewswire

4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS

16 дек 2024 08:00:00 Источник Nasdaq GlobeNewswire